HC Wainwright Predicts Portage Biotech Q1 Earnings

Portage Biotech Inc. (NASDAQ:ALP) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Portage Biotech in a research note issued to investors on Monday, August 17th. HC Wainwright analyst M. Colonnese expects that the company will post earnings of ($0.10) per share for the quarter. HC Wainwright has a “Neutral” rating and a $0.25 price target on the stock. HC Wainwright also issued estimates for Portage Biotech’s Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.28) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Portage Biotech in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Portage Biotech presently has a consensus rating of “Reduce” and an average target price of $0.25.

Portage Biotech Price Performance

Shares of ALP opened at $0.16 on Wednesday. The business’s fifty day moving average is $0.28 and its 200 day moving average is $0.35. Portage Biotech has a 12-month low of $0.15 and a 12-month high of $13.80. The company has a quick ratio of 0.31, a current ratio of 0.31 and a debt-to-equity ratio of 0.01. The stock has a market cap of $3.82 million, a P/E ratio of -0.02 and a beta of 0.61.

Portage Biotech (NASDAQ:ALP) last announced its quarterly earnings results on Thursday, July 16th. The company reported $0.48 earnings per share (EPS) for the quarter. The firm had revenue of $0.05 million during the quarter.

Key Stories Impacting Portage Biotech

Here are the key news stories impacting Portage Biotech this week:

• Positive Sentiment: HC Wainwright assigned Portage Biotech a $0.25 price target, materially above the roughly $0.16 reference price, implying substantial upside if the target is achieved. The initiation of coverage may also improve investor awareness of the company. HC Wainwright Initiates Coverage on Portage Biotech
• Neutral Sentiment: The firm’s official rating is Neutral, indicating that HC Wainwright does not currently see a strong enough catalyst to recommend buying or selling the shares despite the higher price target. Portage Biotech analyst coverage
• Negative Sentiment: HC Wainwright forecasts ongoing losses, including EPS of negative $0.10 in Q1 2027, negative $0.07 in Q2 and Q3, and negative $0.06 in Q4, for a full-year 2027 loss of negative $0.28 per share. For 2028, it projects negative $0.04 EPS in each quarter and a full-year loss of negative $0.17.
• Negative Sentiment: Portage Biotech has a very small market capitalization of approximately $3.8 million and weak liquidity metrics, including a quick ratio and current ratio of 0.31. Its shares also remain near the one-year low, highlighting substantial volatility and financing risk.

Portage Biotech Company Profile

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.